PLGA-hucMSC-Ex Ameliorates Colitis by Reversing Epithelial-mesenchymal Transition

References

1. PanB.T. JohnstoneR.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor.Cell198333396797810.1016/0092‑8674(83)90040‑5
   [Google Scholar]
2. HardingC. HeuserJ. StahlP. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes.J. Cell Biol.198397232933910.1083/jcb.97.2.329 6309857
   [Google Scholar]
3. KalluriR. LeBleuV. The biology, function, and biomedical applications of exosomes.Science20203676478eaau697710.1126/science.aau6977 32029601
   [Google Scholar]
4. OcanseyD.K.W. ZhangL. WangY. Exosome‐mediated effects and applications in inflammatory bowel disease.Biol. Rev. Camb. Philos. Soc.20209551287130710.1111/brv.12608
   [Google Scholar]
5. XieQ. LiuR. JiangJ. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?Stem Cell Res. Ther.202011151910.1186/s13287‑020‑02011‑z
   [Google Scholar]
6. PanX. LiQ. ZhuX. Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease.Sci. Rep.2019911764610.1038/s41598‑019‑54194‑y
   [Google Scholar]
7. QiL. WuJ. ZhuS. Mesenchymal stem cells alleviate inflammatory bowel disease via tr1 cells.Stem Cell Rev. Rep.20221872444245710.1007/s12015‑022‑10353‑9
   [Google Scholar]
8. WeiZ. HangS. Wiredu OcanseyD.K. Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis.J. Nanobiotechnology202321118810.1186/s12951‑023‑01951‑x
   [Google Scholar]
9. LiangX. LiC. SongJ. HucMSC-Exo promote mucosal healing in experimental colitis by accelerating intestinal stem cells and epithelium regeneration via Wnt signaling pathway.Int. J. Nanomedicine2023182799281810.2147/IJN.S402179
   [Google Scholar]
10. LiuC. YanX. ZhangY. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy.J. Nanobiotechnology202220120610.1186/s12951‑022‑01421‑w
    [Google Scholar]
11. TimofeevaA. ParamonikA. SedykhS. NevinskyG. Milk exosomes: Next-generation agents for delivery of anticancer drugs and therapeutic nucleic acids.Int. J. Mol. Sci.202324121019410.3390/ijms241210194
    [Google Scholar]
12. DanhierF. AnsorenaE. SilvaJ. CocoR. Le BretonA. PréatV. PLGA-based nanoparticles: An overview of biomedical applications.J. Control. Release2012161250552210.1016/j.jconrel.2012.01.043 22353619
    [Google Scholar]
13. TangJ. LiT. XiongX. Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells.J. Nanobiotechnology202321146010.1186/s12951‑023‑02228‑z
    [Google Scholar]
14. YangM. ZhangF. YangC. Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer.J. Crohn’s Colitis202014113014110.1093/ecco‑jcc/jjz113
    [Google Scholar]
15. BaoW.L. WuQ. HuB. Oral nanoparticles of SNX10-shRNA plasmids ameliorate mouse colitis.Int. J. Nanomedicine20211634535710.2147/IJN.S286392
    [Google Scholar]
16. XieJ. HuY. SuW. PLGA nanoparticles engineering extracellular vesicles from human umbilical cord mesenchymal stem cells ameliorates polyethylene particles induced periprosthetic osteolysis.J. Nanobiotechnology202321139810.1186/s12951‑023‑02177‑7
    [Google Scholar]
17. KangY. XuC. MengL. DongX. QiM. JiangD. Exosome-functionalized magnesium-organic framework-based scaffolds with osteogenic, angiogenic and anti-inflammatory properties for accelerated bone regeneration.Bioact. Mater.202218264110.1016/j.bioactmat.2022.02.012
    [Google Scholar]
18. YangJ. AntinP. BerxG. Guidelines and definitions for research on epithelial–mesenchymal transition.Nat. Rev. Mol. Cell Biol.202021634135210.1038/s41580‑020‑0237‑9
    [Google Scholar]
19. ZhangN. NgA.S. CaiS. LiQ. YangL. KerrD. Novel therapeutic strategies: Targeting epithelial–mesenchymal transition in colorectal cancer.Lancet Oncol.2021228e358e36810.1016/S1470‑2045(21)00343‑0
    [Google Scholar]
20. LovisaS. GenoveseG. DaneseS. Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.J. Crohn’s Colitis201913565966810.1093/ecco‑jcc/jjy201
    [Google Scholar]
21. WangG. YuanJ. CaiX. HucMSC-exosomes carrying miR-326 inhibit neddylation to relieve inflammatory bowel disease in mice.Clin. Transl. Med.2020102e11310.1002/ctm2.113 32564521
    [Google Scholar]
22. ZhongJ. XiaB. ShanS. High-quality milk exosomes as oral drug delivery system.Biomaterials202127712112610.1016/j.biomaterials.2021.121126
    [Google Scholar]
23. PhilippartM. SchmidtJ. BittnerB. Oral delivery of therapeutic proteins and peptides: An overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens.Drug Res.201666311312010.1055/s‑0035‑1564102
    [Google Scholar]
24. WangL. LiS. LuoH. LuQ. YuS. A comprehensive study on the role of metabolic pathways in cancer therapy.J. Exp. Clin. Cancer Res.20224130310.1186/s13046‑022‑02535‑4
    [Google Scholar]
25. ZhouX. HanJ. ZuoA. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediat ed PI3K/AKT activation in colorectal cancer.Mol. Cancer202423128210.1186/s12943‑024‑02180‑y
    [Google Scholar]